


Vietnamese American Cancer Foundation HỘI UNG THƯ VIỆT MỸ

COVID-19 prevalence & fear among Vietnamese American cancer patients and other community members: a campuscommunity research incubator

Valerie Pham, PhD(c), MSN Becky Nguyen, MPH, MPA Dung Hua, MHA Ilhem Messaoudi, PhD Adeline Nyamathi, PhD, ANP, FAAN Lorren Yniguez, MSN, RN Sanghyuk Shin, PhD

Thursday, May 27, 2021

## BACKGROUND



## BACKGROUND


 Public health info & resources regarding COVID-19 ineffectively trickled into minority communities



## BACKGROUND

- Pandemic of disinformation
- Widespread misunderstanding & frustration





PUBLISHED: March 25, 2020 at 7:14 p.m. | UPDATED: March 27, 2020 at 2:31 p.m.



#### Update: Health officials warn that coronavirus blood test could spell trouble

A Garden Grove physician is likely one of the first practitioners in the U.S. to begin offering a rapid coronavirus screening test popular in Asia that can provide results within 10 minutes through a simple fingerstick.

#### **RESEARCH AIMS**

- Prevalence of SARS-CoV-2 infection among Vietnamese American cancer patients/survivors & other community members
- Assess knowledge, attitude, & fear toward COVID-19
  - Hypothesis: Greater knowledge & positive attitude toward pandemic protective behaviors will result in reduced fear associated with COVID-19

## **METHODS**

- Convenience sampling
- 2-tier phone recruitment VACF client registry
- Bilingual survey (Vietnamese & English) via mail, online, & onsite prior to biospecimen collection
- \$25 cash compensation
- Specimens delivered to processing lab same day
- If PCR COVID-19 +, notification ≤5 business days & referred for confirmatory evaluation

Joint effort VACF + UCI protocol/questionnaire development	Telephone recruitment Survey data collection begins	Biospecimen collection day #1	Biospecimen collection day #2	Data analysis
Pre-study	Nov 2020	Nov 21, 2020	Dec 6, 2020	Dec 2020 to present

### **MEASURES**

- Demographics, social, & health information
- RT PCR RNA detection via oropharyngeal samples
- Antibody assays via blood samples
- Knowledge scale (14 items)
  - T/F questions based on CDC guidelines

## • Attitude scale (10 items)

• Likert-type scale measuring ease/difficulty of engaging in pandemic-appropriate protective behaviors (e.g., social distancing, masking, etc.)

## • Fear scale (7 items)

• Likert-type scale measuring level of agreement to fear statements


# RESULTS


- 152 participants completed all components (blood + saliva + survey)
- 108 completed entire set of fear questions
- 2 w/ PCR+ results
  - Notification & referral for confirmatory evaluation
- 5 w/ antibodies


## **DEMOGRAPHICS (N=108)**


- 70% female
- 57% between 57-84 years old
- 56% describes English fluency as "not well"
- 77% w/ income ≤\$40k
- •91% w/ health insurance
- 55% diagnosed w/ cancer

Selected fear responses









## RESULTS

	Unadjusted & Adjusted Models					
	Base Model (N=98)		Full Model (N=81)			
Variables	B coef. (95% Cl)	P value	B coef. (95% Cl)	P value		
COVID-19 knowledge	-0.71 (-1.40,-0.02)	0.044	-0.74 ( -1.49, 0.01)	0.052		
COVID-19 attitudes	-0.15 ( -0.41, 0.12)	0.280	-0.11 (-0.40, 0.17)	0.431		
			gender, marital stat English fluency, em	ontrolled for variables: ender, marital status, age, nglish fluency, employment, ousehold size, & cancer agnosis		

## CONCLUSION

- Low infection prevalence
- High levels of fear
- No association between attitude & fear
- Negative association between knowledge & fear

Limitation

• Loss of participants due to missing data

Next steps

- Further analysis (cancer vs non-cancer)
- Fear score after vaccination
- Comparison of scores before vs after winter surge

## ACKNOWLEDGEMENTS

- VACF participants
- VACF staff & volunteers
- Messaoudi lab specialists





• Funding provided by:

UCI Institute for Clinical & Translational Science

